Cosmetic composition comprising vesicle concentrate consisting of aqueous solution of lipid vesicles for cosmetic product, cosmetic product comprising said cosmetic composition and method for production thereof
By using specific ingredients in cosmetics, the problems of vesicle stability and release control are solved, the integrity and long-term effectiveness of vesicles in cosmetics are achieved, and the skin care effect is significantly improved.
Patent Information
- Application Number
- CN202380035038.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-20
- Filing Date
- 2023-04-18
- Publication Date
- 2024-11-29
AI Technical Summary
During the preparation of bionic lipid vesicles in existing cosmetics, it is difficult to ensure the integrity and stability of the vesicles, resulting in uncontrolled release of active ingredients, affecting the long-term effectiveness and safety of the product.
Bionic lipid vesicle concentrates containing phospholipids, phytosphingosine, phytosterol, β-phytosterol sulfate and ceramide are used to form a multi-layer vesicle structure through specific processing methods and combine it in cosmetic formulas. Other compatible components ensure that the size distribution of vesicles is between 0.6-1.0 microns, achieving stability and high yields.
It significantly improves the integrity and stability of vesicles, extends the release time of active ingredients, provides immediate and long-term skin care effects, enhances skin barrier function, improves skin elasticity and hydration, and reduces wrinkle visibility.
Smart Images

Figure CN119053316A_ABST
Abstract
Description
[0001] The invention relates to a cosmetic composition comprising a biomimetic lipid vesicle concentrate, which is used for preparing different types of cosmetic products.
[0002] The cosmetic products are products for skin and hair care, as well as for decorating the face, eyes, eyelashes, lips and body.
[0003] More specifically, the present invention relates to a cosmetic product comprising a concentrate of complex colloidal lipid vesicles (liposomes) containing active ingredients, wherein the wall structure of the vesicles comprises phospholipids, phytosphingosine, phytosterols, β-phytosteryl sulfates and other derivatives of phytosterols, ceramides and / or pseudoceramides (synthetic molecules that mimic the structure of natural ceramides), optionally with the addition of fatty acids, moisturizers, emollients and others, and optionally with the presence of active lipophilic molecules.
[0004] Furthermore, the present invention provides an original solution to the problem of preparing vesicles (liposomes) and their introduction into cosmetic formulations in a stable form.
[0005] As is known to all, vesicles (or liposomes) are supramolecular structures made of phospholipids, which are ubiquitous in biological systems and, due to their amphiphilic structure, automatically assemble according to a bilayer wall structure in an aqueous environment, where their hydrophilic parts are in contact with the aqueous environment, while their hydrophobic parts are hidden inside the bilayer.
[0006] In vivo, the vesicles are composed of a supramolecular shell or membrane made of a simple double-layer phospholipid, and have the functions of secretion (exocytosis), transport and internalization (endocytosis) of hydrophilic compounds, playing an important role in intercellular communication.
[0007] Furthermore, it is also known that in vivo, vesicles can embed various compounds, such as membrane proteins and other lipophilic substances, into the membrane, which find a suitable environment within the bilayer.
[0008] Biomimetic lipid vesicles can be made using synthetic phospholipids or phospholipids purified from phospholipids extracted from plant or animal sources.
[0009] It is well known that the permeability of vesicles and their mechanical stability depend on the composition of the lipid mixture forming the membrane and that said properties can be modulated by using lipids with different degrees of unsaturation or by inserting sterols in the membrane.
[0010] Biomimetic lipid vesicles are microstructures comprising one or more concentrically or tubularly arranged lipid bilayers. Different amphiphilic molecules are used in the literature to prepare liposomes, and the method of their preparation can be adjusted to control their size and morphology. Active molecules can be encapsulated in the aqueous space or embedded in the bilipid layer; the exact location of the active molecule in the vesicle depends on the physicochemical structure and lipid composition. In the literature, biomimetic lipid vesicles show great potential as a system for releasing personal care active ingredients. Various molecules, including peptides and proteins, have been incorporated into biomimetic colloidal lipid vesicles through different preparation systems. Due to their high biocompatibility, they are one of the most effective systems for skin delivery and skin treatment of active substances.
[0011] In synthetic vesicles, the organization of the bilayer can be unilamellar (so-called SUV / LUV, small / large unilamellar vesicles) or multilamellar (SMV / LMV small / large multilamellar vesicles), forming unilamellar or multilamellar vesicles, respectively, of varying sizes, with more or less thick shells, or smaller or larger dimensions.
[0012] The size of synthetic lipid vesicles depends on their manufacturing method. In the prior art, different methods for manufacturing synthetic lipid vesicles are provided, mainly by using ultrasound, extrusion through porous membranes, hydration of thin phospholipid membranes or by microfluidics. Such methods do not allow obtaining a high density of vesicles, but allow their size to be precisely determined and are therefore the method of choice in the academic and pharmaceutical fields.
[0013] Especially in the pharmaceutical and biological context, the ability of liposomes to penetrate tissues to release their contents inside cells is of crucial importance. Inside the cell, the active ingredients contained in the vesicles can exert their pharmacological effects. Penetration into tissues is facilitated by making liposomes with nanometer dimensions (diameter <100 nm), and such formulations are therefore very precise and calibrated for this purpose. They are administered under controlled conditions and are subject to rigorous testing. In fact, they are injectable preparations (as in the case of the so-called mRNA vaccines) or used for the in vitro internalization of genetic material through its interaction with the cell membrane.
[0014] Today, consumers are increasingly favoring personal care products that make everyday life healthy and pleasant, improve social relationships, and bring about personal well-being. For these reasons, today's new personal care products are of increasingly higher quality due to the introduction of new complex and performance ingredients. The trend towards product formulations that focus on environmental sustainability and ingredient renewability is particularly strong. In this regard, plant-derived ingredients and compounds taken from the plant world are particularly preferred.
[0015] This consumer demand and new scientific knowledge prompted the applicant to research and develop an innovative project to prepare cosmetic products containing biomimetic vesicles.
[0016] In the cosmetic world, the interest in said vesicle systems stems from the fact that, similar to what happens in living organisms, said vesicles can serve as efficient carriers of hydrophilic and lipophilic active molecules. From the literature, their ability to encapsulate hydrophilic compounds within their aqueous core is known, as is their ability to embed lipophilic compounds within their lipid bilayer shell. Furthermore, it is known that the compounds forming vesicles / liposomes can be chosen from biologically derived substances, mimicking the lipid composition present on the epidermis. They can integrate and improve the barrier properties of the epidermis against external agents and prevent dehydration.
[0017] The encapsulation characteristics of active ingredients can be used to develop personal care products, especially skin care products. In fact, products are offered on the market and described in the literature, characterized by the presence of liposomal vesicles in creams and other topical products. Such products contain, among others, differently functionalized phospholipids, ceramides, fatty acids and sterols, which are essential ingredients for the preparation of liposomes; however, the presence and integrity of the vesicular structures in cosmetic products have not yet been demonstrated. Since the preparation of vesicles is a process that requires complete control over the composition, temperature and stirring intensity to which the phospholipid layer is exposed, their in situ formation in the final composition is far from guaranteed. In a market environment where the claimed properties of cosmetic and personal care products, especially high-end products, must be demonstrated and supported by scientific evidence, there is a need to provide companies with methods and technologies that enable the execution of such claims.
[0018] In fact, the vesicle structure is a structure maintained by supramolecular weak interactions and can be easily destroyed by processing energy, temperature, use of emulsifiers and solvents, leading to different multiphase systems, such as, for example, oil-in-water emulsions.
[0019] The scenario in the cosmetics sector is different from that in the pharmaceutical sector, as many ingredients need to be regulated by fully mastering the often heterogeneous production processes in order to create a pleasing and at the same time functional texture. In addition, the methods described in the academic and patent literature are suitable for the manufacture of liposomes and vesicles with nanometer dimensions (<100nm), which are characterized by increased tissue penetration in vivo. This characteristic is counterproductive in the field of dermocosmetics, where intentionally manufactured structures with dimensions less than 100nm are considered nanomaterials, which is generally an undesirable feature that may be of concern to users.
[0020] Cosmetic formulators have to deal with a wide range of formulation variability, and creating formulations containing intact liposomes / vesicles is a challenge.
[0021] For example, the use of traditional secondary emulsifiers mixed with vesicles is not compatible with phospholipid systems because it disrupts the order of the phospholipid system and compromises its efficacy. One possible formulation strategy is to insert vesicles into polymer gels in order to provide optimal characteristics to the final product, such as ease of use and sensory comfort. These composite structures have unique characteristics in which the stability of the vesicles in the macromolecular system is increased, with higher electrical resistance than free vesicles in solution. Moreover, when the active molecules are placed in the core of the vesicles and the vesicles are included in the gel mesh, both the mesh and the bilayer can best preserve the different active ingredients during transportation. Finally, the controlled release of the active ingredient over time minimizes the problem of "burst release", that is, excessive active ingredient due to release too quickly.
[0022] KR 101440383 B1 describes a cosmetic composition comprising osmotic cells in the form of vesicles, which include a lipid complex of squalene and a human adipocyte stem cell culture medium extract. The osmotic cells are obtained by emulsifying squalene, phospholipids, phytosphingosine, ceramide, cholesterol, phytosterol, and β-sitosterol under high pressure to form a gel-type lipid complex. At room temperature, the complex is added to an aqueous solution including the extract to obtain a vesicle including the extract compounded with squalene in a closed bilayer structure. The osmotic cells essentially include a lipid composition forming a cell membrane, and the purpose of their preparation is to stabilize the heat-labile human adipose stem cell culture extract and promote transdermal absorption (paragraph 0026). The osmotic pressure cells according to the document are characterized in that the size range is 20 to 500nm, preferably 50 to 250nm, and most preferably 100 to 200nm, with an average of 120nm. According to the document, when the average droplet size of the penetration is greater than 500nm, the skin penetration and formulation stability are very weak (paragraph 0029).
[0023] The aim of the present invention is to create cosmetic products comprising biomimetic vesicles for skin care, wherein the integrity of the vesicles is maintained and their beneficial activity on epidermal health is demonstrated.
[0024] Said object is achieved by preparing a cosmetic composition comprising a vesicle concentrate as defined in claim 1 and using said cosmetic concentrate vesicle composition for preparing a cosmetic product as claimed in claim 13.
[0025] The vesicles are specially formulated in a processing step in which only the ingredients necessary for their preparation are combined and processed in a mode that ensures high yield and high concentration of vesicle formation. Subsequently, the vesicles are combined with other cosmetically acceptable and compatible ingredients through a process suitable for maintaining their characteristics.
[0026] The wall of the vesicle is preferably made of the following: phospholipids (including but not limited to: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylinositol phosphate, phosphatidylinositol diphosphate, phosphatidylinositol triphosphate, etc., each with different saturation / unsaturation), monoacyl derivatives of phospholipids (including but not limited to: monoacylphosphatidilcholine), steroid derivatives (including but not limited to phytosterols, β-sitosterol, phytosteryl isostearate, β-phytosterol sulfate, etc.), ceramides and analogs (acylated sphingosine and / or "ceramide-like"), sphingosine and analogs, fatty oils (including but not limited to: squalane), fatty acids (including but not limited to: oleic acid), fatty alcohols (including but not limited to: octyldodecanol), antioxidants, preservatives and optionally active lipophilic molecules. The fatty alcohol and steroid components may optionally be modified with silane functional groups, including but not limited to triethoxysilane functional groups.
[0027] A method for obtaining a cosmetic product according to the invention is defined in claim 15 .
[0028] In particular, the vesicle concentrate of the cosmetic composition of the present invention can be obtained by: allowing the vesicle component (phase A) in a plant-derived humectant (including but not limited to: glycerin, diglycerol, isosorbide, butylene glycol) to reach a molten state (liquid crystal state) until a homogeneous single-phase system is obtained, and introducing an aqueous phase into the system at a temperature higher than the solidification temperature of the lipid phase to organize the liquid crystal lipid phase into a multilamellar vesicle structure.
[0029] The active ingredients (Phase B) that can be inserted into the vesicle concentrate are preferably of plant origin, including but not limited to: stearyl glycyrrhetinate, magnolia acuminata bark extract, betula alba bark extract, centella asiatica leaf extract, jania rubens extract, tocopheryl acetate, hydroxypinacolone retinoate, linolenic acid and linoleic acid, ascorbyl tetraisopalmitate, 3-o-ethyl ascorbic acid, niacinamide, oligofructose, beta vulgaris (beet) root extract, tranexamic acid, sophora japonica extract, hexylresorcinol, undecylenylphenylalanine, salicylic acid, salix alba bark extract, zinc pyrithione, brassica campestris (rapeseed) flower extract, candida bumblebee (Bombus spp.) extract, serrata oleracea (Sophora japonica ... bombicola / rapeseed oil fermented extract, undecylenic acid and derivatives, climbazole, quillaja saponaria bark extract, cupressus sempervirens fruit extract, arctium majus root extract, 10-hydroxydecanoic acid, sebacic acid, zinc pca, caprylic acid, fig (fig) fruit / leaf extract, urtica dioica extract, hydrolyzed yeast protein, kigelia africana fruit extract, ginkgo biloba leaf extract, basilicum hairy root culture extract, caffeine, neoruscogenin, ruscogenin, betaine, avena sativa, zanthoxylum alatum fruit extract, Brassica napus campestris (rapeseed) sterols, epilobium angustifolium flower / leaf / stem extract, hydrogenated starch hydrolyzate, ascophyllum nodosum extract, asparagopsis armata extract.
[0030] The concentration of the lipid component of the vesicles may range from 15 to 40% by weight of the vesicle concentrate.
[0031] The aqueous phase comprises water and may optionally include humectants (including but not limited to glycerol, diglycerol, isosorbide, butylene glycol), salts, preservatives, acidity regulators (including but not limited to lactic acid, citric acid, sodium hydroxide, arginine), rheology modifiers, hydrophilic actives, and any other hydrophilic cosmetically acceptable compounds.
[0032] The system is then placed at the solidification temperature of the lipid phase and it looks like a material with a pasty texture, with rheological characteristics of a pseudoplastic fluid (shear thinning, or becoming more fluid under the action of increasing shear rate) or a viscoelastic solid (elastic modulus at low strains is higher than the viscous modulus, with a reversal between the moduli at high strains). The size distribution of the vesicles thus prepared ranges from 0.6 to 1.0 microns, with an average size of 0.8 to 1 μm (determined by laser diffraction) and depends on the intensity of the shear forces applied during the concentrate manufacturing step.
[0033] In particular, with reference to Example 1 and the following examples, the vesicle concentrate can be obtained by inserting the ingredients of phase A one at a time into a jacketed mixer equipped with a turbine (rotor-stator), mechanical stirring of blades at room temperature, and a wiper. The mixture is then mechanically stirred at room temperature until a homogeneous and smooth dispersion of the components is obtained. Phase A is gradually heated in increments of 10° C. over a period of 1 h until the temperature reaches 80-100° C. to allow the solid ingredients to fuse, obtaining a translucent dispersion with a paste-like texture and a slightly yellowish color. Phase A is then heated to 60° C., mechanical stirring is continued, and phase B is gradually added to the mixer to keep the system at a constant temperature. Once the addition of phase B is completed, the composition is kept under stirring for 30 minutes. Finally, a concentrate having a white / light yellow paste appearance is obtained by using a turbine for turbulent stirring, and the temperature is gradually reduced to room temperature. The vesicle concentrate thus obtained can be diluted in water and other ingredients to obtain the formulations of Example 4 and the following examples.
[0034] The cosmetic product is obtained by combining the vesicle concentrate with water and hydrophilic ingredients such as humectants (including but not limited to glycerol, diglycerol, isosorbide, butylene glycol), salts, preservatives, acidity regulators (including but not limited to lactic acid, citric acid, sodium hydroxide, arginine), rheology modifiers (including but not limited to polyquaternium-37, polyacrylates, polysaccharides, xanthan gum, bentonite), hydrophilic active substances and any other hydrophilic cosmetically acceptable compounds. Moreover, cosmetically acceptable lipophilic ingredients such as oils, waxes, silicones and derivatives can be optionally integrated into the formulation. The concentrate is present in the cosmetic product in an amount of 0.1-99.99% (by weight) of the final product and is mixed with other cosmetic ingredients under conditions where the integrity of the vesicles is not compromised.
[0035] In summary, the method for obtaining a cosmetic product according to claim 13 or 14 comprises the following steps:
[0036] Preparation of plant-derived plant or biomimetic vesicles having a size range of 0.6-1.0 micrometers, wherein the wall comprises a lipid phase having the above-mentioned composition, by performing the following sub-steps:
[0037] o preparing a composition comprising a vesicle concentrate by melting the walls of the vesicles to a liquid crystal state to obtain a homogeneous single-phase system;
[0038] o introducing an aqueous phase into the vesicle concentrate composition at a temperature above the solidification temperature of the lipid phase of the vesicles;
[0039] o cooling the vesicle concentrate composition at the solidification temperature of the vesicle lipid phase until a paste-like material having the rheological characteristics of a pseudoplastic fluid or a viscoelastic solid is obtained, and the size distribution of the vesicles is in the range of 0.6-1.0 microns;
[0040] • The vesicle concentrate composition having a paste-like texture is mixed with water and other cosmetic ingredients until a final cosmetic product containing the desired percentage (by weight) of the vesicle concentrate is obtained.
[0041] It is worth pointing out that the composition prepared according to the present invention preferably contains only raw material ingredients of plant origin.
[0042] Among cholesterol-like molecules, phytosterol is a general term denoting molecules of plant origin; beta-sitosterol sulfate belongs to this class and is chemically identical to cholesterol sulfate of animal origin, as does phytosteryl isostearate (an ester).
[0043] The use of phytosterols in the form of sulfates makes the composition characteristics of the present invention different from ordinary cholesterol of both animal and plant origin. For more information, please see the review: Strott and Higashi Cholesterol sulfate in human physiology: what's it all about? Journal of Lipid Research, 2003 (44): 1268-1278. The review explains that cholesterol sulfate is a component of cell membranes and can be found in human plasma. Surprisingly, it shows regulatory functions, indicating similarities to compounds classified as hormones. In particular, it plays an important role in the differentiation of keratinocytes and the development of the epidermal barrier. It is believed that cholesterol sulfate plays an important role in the normal function of the stratum corneum and the normal shedding of dead cells. A reduction in the cholesterol sulfate content in the stratum corneum reduces the stability of the bilayer and reduces the lipid fraction arranged in the lateral accumulation of the liquid, thereby resulting in a reduction in the elasticity of the lipid phase and hindering the correct orientation of the corneocyte lipid lamellae. Cholesterol sulfate has been shown to have a regulatory effect on the transcriptional activity of specific keratinocyte genes.
[0044] As mentioned in the introduction, it is known in the art to use liposomes to transport active molecules and help them penetrate into cells; KR 101440383 B1 also discloses osmotic cells containing human adipocyte stem cell culture medium extract.
[0045] Surprisingly, upon skin application of the present invention, improvements in skin condition were noted as early as 6 hours (see Fig. 9 ), which is inconsistent with the effect attributed to the active ingredient contained in the vesicles. Moreover, it is also interesting that one week after stopping the application of the cream according to the invention, the hydration returned to the initial value (see points 5.1.2 and 5.1.3).
[0046] These observations can only be explained by considering that the vesicle concentrates (and formulations containing different percentages) can deposit a continuous film made of non-volatile ingredients (lipid shell of the vesicles) with lateral dimensions of the order of micrometers. Such evidence is provided by sensory observations of the product texture (feeling of emollient and nourishing film) and instrumental observations (TEM images of vesicles after deposition and evaporation of the aqueous ingredient, see Fig.16 and 17 ) was demonstrated. The vesicle structure is maintained in the presence of the active ingredient; the film-forming and nourishing capabilities are also present when the active ingredient is present and allow for an immediate effect that is observed within a few hours. In addition to the short-term film-forming effect, a long-term effect is added, which is due to repeated exposure to the specific active ingredient, improving the functionality of the concentrate on a time scale compatible with changes in cellular metabolism (clinical testing of two to four weeks).
[0047] Furthermore, the present invention relates to the preparation of a cosmetic water-based product for decorating the face, eyes, eyelashes, lips and body comprising said vesicle concentrate and a cosmetically acceptable pigment.
[0048] Finally, the invention relates to the manufacture of cosmetic powders obtained by combining a vesicle concentrate with a powder and removing the aqueous phase by an additional evaporation process.
[0049] One of the main functions of the skin is to protect the organism from environmental factors such as UV radiation, microorganisms, physical and chemical factors. The entire surface of our skin is covered with a basic lipid layer, forming a protective layer. This lipid layer is called the cutaneous hydrolipidic film, which mainly consists of lipids (95%) and has an acid pH of 4.9.
[0050] The integrity of the hydrolipidic film is essential to maintain soft and hydrated skin, protect the body from external microorganisms, reduce the risk of infection, and regulate the absorption and excretion of substances through the skin.
[0051] In fact, said lipids ensure reduced water dispersion, reduced electrolyte dispersion, natural defense against microorganisms and cementation of keratinocytes.
[0052] Formulas containing vesicle concentrates show efficacy in the following areas: strengthening the skin barrier, skin regeneration, anti-aging (or pro-age) activity, increasing skin hydration, immediate effect, improving skin elasticity and skin firmness, reducing wrinkle visibility, stimulating and increasing the production of type I collagen, stimulating and increasing the activity of aquaporin 3 channels, retinol-like activity.
[0053] The efficacy is shown in the formulation examples of vesicle concentrates and derived cosmetic products disclosed at the end of this specification.
[0054] Figure 1 and Figure 2 Shown are images of the vesicle concentrate of Example 1 obtained by transmission electron microscopy (TEM). The images show the multilamellar morphology and characteristic size of the vesicle structure produced by the present invention (left: scale bar 500 nm, right: scale bar 200 nm).
[0055] Figure 3 Shown are images relating to the vesicle concentrate of Example 2 obtained by transmission electron microscopy (cryo-TEM) of a frozen sample, showing intact vesicles.
[0056] Figure 4Shown are images obtained by transmission electron microscopy (cryo-TEM) of frozen samples relating to the cream formulation of Example 4, wherein the vesicle concentrate of Example 2 is 10% (by weight). The vesicle structure is preserved.
[0057] In particular, the experimental tests of Example 1 were performed and are summarized as follows.
[0058] 1) Evaluation of the therapeutic effect of the vesicle concentrate according to Example 1
[0059] The efficacy of the vesicle concentrate according to Example 1 was demonstrated by an extensive testing strategy using a fairly complete set of in vitro, ex vivo and in vivo (clinical testing) tests.
[0060] Activity of vesicle concentrates
[0061] Based on the observations, when used in cosmetic formulations, the vesicle concentrate according to Example 1 can be considered effective in the following aspects:
[0062] -Skin barrier enhancement
[0063] -Protection and repair of human skin barrier
[0064] - Skin regeneration
[0065] - Anti-aging / youth-promoting activity
[0066] -Instantly increases skin moisture
[0067] - Improve skin elasticity and firmness in a short period of time
[0068] - Reduced visibility of wrinkles
[0069] - Improve overall skin condition
[0070] -General direct and perceptible impact
[0071] -Highly potent retinol-like activity.
[0072] Efficacy of vesicle concentrates
[0073] In order to show the efficacy of the vesicle concentrate according to Example 1, specific endpoints upon use were correlated with skin barrier and skin regeneration activity.
[0074] Effects related to skin barrier / renewal / regeneration activity
[0075] Different endpoints were chosen for in vitro studies in cell culture and ex vivo studies in human skin explants: production of aquaporin-3 (AQP3) and synthesis of type I procollagen.
[0076] Evaluation of non-cytotoxic concentrations used in cell culture: MTT (HaCaT) on keratinocytes
[0077] Preliminary tests of cytotoxicity (MTT assay of HaCaT cells treated with increasing concentrations of vesicle concentrate for 48 h) were performed to select the highest non-cytotoxic dose of vesicle concentrate (0.011% and 0.017%) for the following in vitro studies.
[0078] Collagen Type I
[0079] Collagen is the main structural protein of the extracellular matrix; it can be found in all the different connective tissues of animals. Type I collagen is one of the most representative (most abundant) collagens in the skin and is an essential "scaffolding" protein that gives the skin its strength and structure.
[0080] Type I collagen production decreases with age, which reduces skin smoothness and elasticity and increases wrinkle formation.
[0081] Procollagen is the precursor of collagen. Type I procollagen is a new type of collagen synthesized in the skin. Increasing collagen synthesis fights skin aging and improves skin health.
[0082] Production of Type I Collagen—In vitro evaluation of cell culture using two different concentrations of the vesicle concentrate according to Example 1
[0083] The test monitors the synthesis of new type I collagen by quantifying type I procollagen using an ELISA test on cell cultures made from a monolayer of normal human dermal fibroblasts (NHDF) using specific antibodies.
[0084] Two aqueous dispersions of the vesicle concentrate according to Example 1 were applied to the culture medium at 0.01% and 0.017% for 24 hours. The peptide TGFβ (transforming growth factor β1), a natural growth factor involved in tissue repair, was used as a positive control. Three independent tests were performed, each in triplicate.
[0085] result
[0086] like Figure 5 As shown (*=p value 0.05; **=p value 0.01; ***=p value 0.001), the vesicle concentrate significantly increased the synthesis of type I procollagen by 20% in both tested dilutions, indicating the production of type I collagen and especially its in vitro evaluation on cell culture.
[0087] Production of Type I Collagen—Ex vivo evaluation of cell cultures using three different concentrations of the vesicle concentrate according to Example 1
[0088] To confirm the effect of the vesicle concentrate on stimulating the synthesis of type I collagen, biopsies from human skin explants were treated with glycerol solutions of vesicle concentrate at three different concentrations (1%, 5%, 20%). The control samples contained only glycerol, while as a positive control, TGFβ (transforming growth factor β1), a natural factor involved in tissue regeneration, was used.
[0089] The abundance of type I collagen was detected by immunofluorescence and The fluorescence intensity was calculated by software.Three independent experiments were performed, each in triplicate.
[0090] result
[0091] like Figure 6 As shown (*=p value 0.05; **=p value 0.01), even at the lowest concentration tested (1%), the vesicle concentrate increased the production of type I collagen by 40%. This effect was not dose-dependent and was comparable to the results produced by the positive control.
[0092] exist Figure 6 middle:
[0093] Left: Graph showing the percentage increase in type I collagen production relative to a control blank sample (set to 100%) and relative to the positive control TGFβ.
[0094] Right: Immunofluorescence image of a skin explant section localizing the majority of newly formed type I collagen in the upper layers of the skin close to the epidermis.
[0095] Therefore, it can be concluded that even low percentages of vesicle concentrates can significantly stimulate new collagen synthesis both in vitro and ex vivo by monitoring the production of type I procollagen.
[0096] Aquaporin 3 (AQP3)
[0097] Aquaporin 3 (AQP3) is the protein product of the human gene AQP3. It is expressed in many tissues, such as the skin, where it acts as a membrane transporter for water and glycerol. It is one of the most important channels for water and glycerol in the epidermis, regulating skin hydration, thereby maintaining its good healthy balance.
[0098] Aquaporins (AQPs) are essential for maintaining water homeostasis; Aquaporin 3 channels (AQP3) are highly expressed in the basal layer of normal skin keratinocytes and are the most important passive transporters of water and glycerol in the epidermis; they regulate skin hydration by balancing it, and therefore, they maintain good health and function (e.g. elasticity) of the skin. A significant decrease in skin water content and skin elasticity was observed in mice in which AQP3 expression was inhibited.
[0099] Therefore, AQP3 plays an important role in maintaining skin hydration and normal function.
[0100] AQP3 Production—In vitro evaluation of cell cultures was performed using two different concentrations of the vesicle concentrate according to Example 1 .
[0101] In this test, the efficacy of the vesicle concentrate in increasing aquaporin-3 expression was evaluated compared to the known active ingredient Bakuchiol (used as a positive control).
[0102] Bakuchiol is a known natural active ingredient with many cosmetic properties (anti-wrinkle, effective for acne-prone skin, stimulates elastin production, lightens dark spots), making it a safer natural alternative to retinol with similar anti-aging benefits. In this test, Bakuchiol was chosen as a positive control due to its ability to stimulate AQPS synthesis, as shown in the literature (DOI: 10.1111 / ics.12117).
[0103] Two aqueous dispersions of the vesicle concentrate (0.011% and 0.017%) were applied for 24 hours on cell cultures made of monolayers of human keratinocytes (human keratinocytes—HaCaT).
[0104] The amount of expressed AQPS was assessed using ELISA plates with specific antibodies. Three independent experiments were run, each in triplicate. Results were calculated as mean values.
[0105] result
[0106] Vesicle concentrate ( Figure 7 ) showed very good activity, increasing AQP3 in both tested dilutions (0.010% and 0.017%) - using a dose response model - achieving very similar effects to Bakuchiol at its commonly used concentrations.
[0107] The histogram shows the percentage increase of AQP3 compared to the blank control (100%) and the positive control Bakuchiol (***=p value ≤ 0.001%).
[0108] AQP3 Production—Cell cultures were evaluated ex vivo using three different concentrations of the vesicle concentrate according to Example 1 .
[0109] To confirm the stimulatory effect of the vesicle concentrate produced by the above in vitro test on AQP3, biopsies from human explants were treated topically with glycerol solutions of three different concentrations (1%, 5%, 20%) of the vesicle concentrate (Example 1). The expression of AQP3 was detected by immunohistofluorescence. Three independent experiments were performed, each in triplicate, and the results were calculated as the mean. Retinol and Bakuchiol, known as activators of AQP3, were selected as positive controls.
[0110] result
[0111] Figure 8 The graph (* = p value p 0.05; ** = p value 0.01; *** = p value 0.001) shows Fluorescence intensity detected by the software: All tested concentrations of vesicle concentrate significantly increased the production of AQP3 channels. More interestingly, 5% vesicle concentrate increased AQP3 more than three times that of retinol and almost twice that of Bakuchiol.
[0112] exist Figure 8 middle:
[0113] Left: The graph shows the percent increase in AQP3 compared to a control blank (set to 100%) and two positive controls: Bakuchiol and Retinoic Acid.
[0114] Right: Immunohistofluorescence image of a skin explant section localizing AQP3 water channels.
[0115] From in vitro and ex vivo studies of aquaporin 3 channels the following can be inferred:
[0116] In both in vitro and ex vivo studies, vesicle concentrates significantly increased aquaporin 3 channels;
[0117] On this parameter, the vesicle concentrate was more effective than the well-known AQP3 activators Retinol and Bakuchiol.
[0118] Clinical research on vesicle concentrate system
[0119] Based on the excellent results from in vitro and ex vivo experiments, a testing strategy for clinical evaluation of vesicle concentrates was established.
[0120] Specific study endpoints were chosen to evaluate the anti-aging activity of the vesicle concentrate, with a particular focus on its efficacy as a skin barrier and skin regeneration.
[0121] The results summarized below were confirmed by two different full studies:
[0122] - The first study investigated the function of increasing the percentage of vesicle concentrate (Example 1) in the base formula of a face cream;
[0123] - The second study explored vesicle concentrate systems containing different amounts of constituent ingredients to investigate the flexibility of vesicle concentrates as a platform rather than a cosmetic co-active ingredient made with a specific formulation.
[0124] 4.1 Clinical studies of the vesicle concentrate according to Example 1 at increasing percentage concentrations
[0125] In this first study, five basic cream formulations were prepared with increasing percentages of vesicle concentrate: 0% (placebo), 1%, 5%, 10%, 20%. Clinical evaluation tests were performed on 50 volunteers (aged 40-65 years, female), divided into 5 groups of 10 volunteers each; each group was assigned one of the five formulations.
[0126] First, the product was applied to their faces under controlled conditions at a clinical center; the volunteers used the application product twice a day (morning and evening) continuously for a period of 4 consecutive weeks (28 days).
[0127] To evaluate the anti-aging efficacy of the vesicular concentrates, especially their effects on the skin barrier and their skin renewal / regeneration activity, three different evaluation methods were chosen:
[0128] 4.1.1 Hydration (assessed by corneal measurement),
[0129] 4.1.2 Skin elasticity (measured by cutometry),
[0130] 4.1.3 Wrinkle visibility (by digital image analysis).
[0131] Instrumental measurements were performed on the faces of volunteers treated with the product (test area) and on untreated areas of the forearms (control area). The measurements were performed at different times (short term: 6 hours after first application; mid-term: 14 days; long-term: 28 days) and compared with the basal values obtained at time 0 according to the scheme in the table below:
[0132]
[0133] The 2-week and 4-week measurements were taken approximately 4 hours after the last application of the product.
[0134] Taking into account the effects of temperature and relative humidity on the skin, volunteers were kept under controlled conditions (range: 22±2°C and 50±5%, respectively) for at least 20 minutes before measurement.
[0135] 4.1.1 Skin hydration (assessed by corneometry)
[0136] Skin hydration is a direct universal parameter that controls overall the well-being and function of the skin. Any alteration of the skin barrier due to physical, chemical or aging factors results in a decrease in the skin's hydration level.
[0137] This study evaluated the hydration efficacy of the vesicle concentrate according to Example 1 by instrumental measurement of the skin hydration status (corneometer CM 825 - Courage + Khazaka) after a single application and repeated daily application for 14 consecutive days. The collected data were statistically evaluated by comparison of the means with a two-tailed t-test.
[0138] result
[0139] Fig. 9 A graphical representation of the results is shown, showing the percentage change in skin hydration values measured for treated and untreated areas at different times compared to the respective basal values at time 0.
[0140] The graph shows the percentage change in skin hydration values after a single application (t6h) and after two weeks of twice daily application of the test product (t2weeks) compared to the corresponding basal values (tb) of the treated area (face) and the control untreated area (forearm) at the same measurement time.
[0141] Also shown are the calculated quadratic correlation functions and their corresponding equations for the values of the treated area after 6 hours and 14 days.
[0142] The vesicular concentrate was shown to be effective in significantly hydrating the outer layer of the skin: the mean hydration level of the facial areas treated with the vesicular concentrate at all concentrations increased significantly (p<0.05) compared to the basal value 6 hours after a single application and after 2 weeks of daily use of the test product; no significant changes were detected in the control untreated areas.
[0143] The good increase in skin hydration values after only one application was maintained after two weeks of product use: this suggests an immediate benefit of the vesicular concentrate, which is able to "melt" with the skin and create a unique "shield" that physically protects it: in fact, at two different reading times (6 hours and 14 days), almost identical hydration values were detected in all groups - no cumulative effect - and this suggests that the vesicular concentrate interacts physically with the skin, rather than with the metabolic system.
[0144] This effect was also confirmed by the practical linear correlation of the dose-effect response detected at the different percentages of vesicle concentrate tested (1%, 5%, 10%, 20%): the hydration level achieved was proportional to the amount of vesicle concentrate in both series (measurements after 6 hours and after 14 days). [Data were consistent with the quadratic distribution (R 2 =0.9813 and R 2 = 0.9632) is the best correlation, but is very close to a linear distribution because the quadratic coefficient is negligible in both correlations (ref. Fig. 9 )].
[0145] No minimum dose was detected to trigger an effect, nor was a plateau reached within the concentration range tested.
[0146] These results regarding hydration were confirmed by a second study described below, which performed such an assessment among the endpoints considered.
[0147] Thus, at all percentages tested, the vesicle concentrate was effective in hydrating significantly more of the outer skin layers.
[0148] Its effect is immediate: just one application of the cream containing the vesicular concentrate on the face (measured after 2 and 6 hours) results in a good increase in hydration levels, which remain unchanged throughout the skin application period. This result explains the immediate benefit provided by the vesicular concentrate, which is able to create a unique "micro-film" on the skin that physically protects it - because it interacts and merges with the skin rather than interacting with its metabolism. In fact, after suspending the use of all the different cosmetic products containing the vesicular concentrate studied for 7 days, skin hydration returned to its initial basal value.
[0149] • This effect was also confirmed by an excellent linear dose-response correlation: the increase in hydration values was proportional to the tested amount of vesicle concentrate (1%, 5%, 10%, 20%).
[0150] It was determined that no minimum amount of vesicle concentrate was required to elicit its hydration effect, nor was there a stable period beyond a given dose.
[0151] 4.1.2 Skin elasticity: firmness and elasticity properties (measured by skin elasticity)
[0152] Under the same study conditions, the vesicle concentrate according to Example 1 was tested for its efficacy in improving skin firmness and elasticity.
[0153] The aim of the study was to evaluate the efficacy of a cream containing increasing amounts of a vesicle concentrate (0% - placebo; 1%, 5%, 10%, 20%) in improving skin elasticity after repeated daily applications compared to an untreated area (forearm) over a total period of 4 weeks.
[0154] The method is based on the instrumental evaluation of the ability of the skin to return to its initial position after suction under standardized conditions. The measuring principle consists in applying a defined depression to the skin of the test area via a circular hole (2 mm in diameter) in the instrument probe (Cutometer MPA 580-Courage+Khazaka). A surgical mode with a low and constant pressure level is used: the skin is sucked into the probe by a uniform vacuum for a specific time and then returns to its original position when the pressure is released. The experimental conditions are:
[0155] - suction time = 1 second;
[0156] - Release time = 1 second;
[0157] - Pressure = 450 mbar
[0158] Repeat the measurement for 3 consecutive cycles.
[0159] The volunteers applied the cream on their face: the volar forearm area served as an untreated control. To ensure that measurements were taken at the same location at different times, a reference mask was used for both the treated and untreated areas. The facial measurements were taken in the zygomatic area. To randomize the conditions of use, measurements were taken on the zygomatic and volar right areas for 25 volunteers and on the left area for the remaining 25 volunteers.
[0160] Measurements were taken on both treated and untreated areas before product application (basal reading, -tb), two weeks after application (t2w), and two more weeks after application (total 4 weeks, -t4w).
[0161] In this skin elasticity measurement test, the percentage increase / decrease of the two most important parameters in this type of study: R0 and R2 ( Fig.10 ).
[0162] Skin elasticity parameter R0( Fig.10 ) measures the maximum depth (in mm) of skin penetration of the probe when vacuum is applied (R0 = Uf); it indicates the flexibility of the skin and reflects the firmness / pliability of the skin; it represents the passive behavior to the forces applied to the skin. Improved skin firmness generally means a decrease in R0 (the skin is less affected by suction).
[0163] The skin elasticity parameter R2 measures the ability of the skin to return to its initial state after the vacuum has ceased; it reflects the total skin elasticity—recovery / deformation—and is calculated according to the following formula:
[0164] R2=Ua / Uf,
[0165] in( Fig.10 ):
[0166] Uf is the maximum expansion of the skin at the end of the vacuum application period (i.e., Uf = R0)
[0167] Ua is the total recovery of the skin to its original position 1 second after cessation of vacuum application (also defined as "total elastic recovery / deformation"). Its value is expressed as a percentage.
[0168] Therefore, the parameter R2 reflects the elastic properties of the skin: it represents the ratio between the width of deformation after suction and the ability to recover the initial position (relaxation / suction). The higher the recovery portion (time delay recovery), the better the elasticity of the skin.
[0169] Improvements in skin elasticity are usually manifested as an increase in the R2 value.
[0170] The maximum penetration depth (mm) of the skin into the probe when vacuum is applied is defined as R0 (=Uf).
[0171] The ability of the skin to recover to its initial state after cessation of the vacuum is defined as R2:Ua / Uf, where Uf is the maximum expansion of the skin in the probe at the end of the suction period (Uf=R0) and Ua is the total recovery of the skin to its initial state after one second at normal pressure.
[0172] result
[0173] The mean R0 values of the facial skin treated with the vesicle concentrate at all tested concentrations (20%, 10%, 5% and 1%) after 2 and 4 weeks of twice daily application ( Fig.11 ), which was significantly decreased compared with the baseline value (p<0.05).
[0174] By comparing the change in R0 with the percentage increase in the vesicle concentrate contained in the test cream in the two series of data (2-week and 4-week application), an excellent, almost linear, dose-response correlation was found. [Again, the data were best correlated with a quadratic distribution (R 2 = 0.9975 and R 2 =0.987), but is in fact very close to a linear relationship because the coefficient of the quadratic term is very small and can therefore be ignored in both correlations].
[0175] Mean values of R2 for the skin of the facial area treated with 20%, 10%, 5% and 1% vesicle concentrate after 2 and 4 weeks of twice daily application ( Fig.12 ), which was significantly increased compared with the initial basal value (p<0.05).
[0176] In this case, by comparing two series of data (2 weeks: R 2 =0.9943; 4 weeks: R 2 =0.9464), an excellent, almost linear, dose-response correlation was also found for the R2 percentage change of the increment of vesicle concentrate in the test formulation.
[0177] In contrast, in the control area (untreated forearm), no statistically significant changes were found for both R0 and R2.
[0178] For the parameters R0 and R2, no significant changes (respectively decreases and increases) were found after 4 weeks of use of the product, at all the amounts of vesicle concentrate tested, relative to the values observed after the first two weeks.
[0179] As with the hydration studies, these results again reflect the immediate impact of the vesicular concentrate on the skin: effective improvements in skin elasticity were achieved within a relatively short application period (2 weeks).
[0180] Fig.11 The graph shows the mean percentage change of the parameter R0 (firmness) of the treated area (face) and similar values of the untreated area (forearm) at the same measurement time compared to the initial value before treatment (baseline, tb) after using the cream under evaluation twice a day for 2 and 4 consecutive weeks (t2 weeks, t4 weeks). The quadratic correlation curves and correlation equations of the two series (2w and 4w) are also shown.
[0181] Fig.12 The histogram shows the average percentage change of the parameter R2 (skin elasticity) in the treated facial area compared to the similar value of the untreated control area (forearm) after applying the test product (t2 week, t4 week) every day for 2 and 4 consecutive weeks, relative to the pre-treatment basal value (tb). The linear correlation curves and correlation equations of the two series (2w and 4w) are also shown.
[0182] Thus, the study showed that the vesicle concentrate was effective in linearly improving skin firmness / pliability (parameter R0) and elasticity properties (parameter R2) of the treated facial skin.
[0183] For the parameters R0 and R2, an excellent linear dose-response correlation was found.
[0184] · After using the product for only two weeks, a high efficacy of improving skin elasticity properties was obtained, thus verifying a short-term effect, i.e., an effect can be seen in a short period of time.
[0185] 4.1.3 Wrinkles: Wrinkle visibility coefficient (by image analysis).
[0186] The surface of healthy skin presents fine mesh grooves that are approximately straight lines, called "skin micro-grains" or "skin textures." This texture is composed of parallel grooves of different depths, which intersect to form rectangles, squares, diamonds, trapezoids and triangles.
[0187] The first consequence of this complex network of lines is that the effective surface area of the human body increases by 10%-50% relative to its apparent surface area. This facilitates the exchange between the epidermis and the environment, improving respiration, heat dissipation and long-distance evacuation of perspiration and sebum, thus maintaining optimal hydration values.
[0188] Moreover, this texture helps the skin's ductility.
[0189] The appearance of skin micro-lines changes with age: the highly regular groove pattern in healthy, young skin is gradually replaced by a more disordered structure characterized by a decrease in the density of lines and an increase in their depth.
[0190] The vesicle concentrate was tested for its efficacy in restoring normal characteristics of micro-lines, reducing the appearance of fine lines, and improving skin smoothness and overall skin appearance.
[0191] The selected method is based on the visibility of wrinkles in facial photographs (high-quality standardized photographs taken under parallel polarized light, frontal and / or profile + / - 45° - HeadScan Dynamics, OrionTechnoLab, France) ( Fig.13 ). Dedicated software ensures the acquisition of images under reproducible lighting and shooting conditions. The photographic system employed is made with a Nikon camera equipped with a 24Mpx sensor. The continuous spectrum lighting has a CRI of 96 and a color temperature of 4500K°. The system is also equipped with an internal 24-color chart, allowing real-time control of the chromaticity and correct display of the image.
[0192] The potential efficacy of cream-based formulations containing increasing percentages of vesicle concentrate (0%: placebo; 1%; 5%; 10%; 20%) in improving (reducing) wrinkle visibility was evaluated in a group of 50 volunteers (Caucasian women, aged 44-66 years) - 10 volunteers for each formulation. Each group applied the designated formulation twice a day for 4 consecutive weeks, while three measurements (image acquisitions) were performed: once before product application (tb), once after 2 weeks of application (t2w), and the last at the end of 4 weeks of use (t4w). The facial area selected for measurement was the lateral periocular area ( Fig.13 ).
[0193] Different parameters were calculated from these images obtained for each volunteer on the same facial area at different treatment times using software dedicated to digital image analysis (FrameScan V3, Orion TechnoLab, France), allowing the evaluation of the intensity of facial wrinkles by measuring the contrast of the images (number of lines, wrinkle size, contrast between wrinkles and their surroundings).
[0194] A wrinkle visibility index was then calculated—which correlated strongly with their clinical perception:
[0195] Visibility coefficient = (wrinkle occupancy) * (comparative wrinkles / skin) * 100
[0196] This index is not just a measure of wrinkle depth (as obtained by 3D analysis), it is a numerical evaluation of the appearance of wrinkles and their visual perception.
[0197] In this experiment, the reduction in the appearance of wrinkles corresponds to a decrease in the value of the visibility coefficient, e.g. Fig.13 , which shows photographs of the same facial area taken of volunteers n.1 and n.2 at tb (before treatment) and after 2 and 4 weeks of product use. The image analysis software allows the calculation of the differences between them by measuring their contrast. By visual (clinical) observation of the images at different times, a qualitative assessment of the wrinkle reduction is already possible.
[0198] result
[0199] The results of this study are summarized in Fig.14 The figure shows the mean percentage change in the wrinkle visibility index of the treated facial areas relative to the base value (tb) after 2 and 4 consecutive weeks of application of the product (twice a day).
[0200] Linear correlation curves for the two series of values at 2 and 4 weeks and their respective equations are also provided.
[0201] After 2 weeks of daily application of the products under test, the wrinkle visibility factor of the facial areas treated with all formulations containing the vesicle concentrate was significantly reduced relative to the initial baseline value. Therefore, the vesicle concentrate is effective in significantly reducing the visibility of wrinkles at all tested concentrations, and this effect is achieved within a relatively short period of use (2 weeks).
[0202] For both sets of data, the reduction in wrinkle visibility was linearly correlated with the amount of vesicle concentrate applied to the skin (after 2 weeks: R2 = 0.9973; after 4 weeks: R2 = 0.9927).
[0203] In the case of this clinical study, there was no further reduction in the wrinkle visibility index after two weeks of use (the difference between the values at 2 and 4 weeks for each concentration of vesicular concentrate was not statistically significant). This result once again demonstrates the "fast" effect associated with the "physical" benefits that the vesicular concentrate provides to the skin.
[0204] The vesicle concentrate system was effective in significantly reducing the visibility of wrinkles at all concentrations tested.
[0205] The reduction in wrinkle visibility is linearly related to the amount of vesicle concentrate applied to the skin.
[0206] This beneficial effect was achieved in a relatively short period of 2 weeks, again illustrating the “rapid efficacy” associated with the beneficial physical interaction of the vesicular concentrate with the skin.
[0207] These results regarding wrinkle visibility were confirmed by a second study described later in this document, which evaluated the endpoint under consideration.
[0208] Overall, for all three endpoints considered in the above studies (hydration, skin firmness, wrinkle visibility):
[0209] All tested amounts of vesicle concentrate were effective, with an excellent linear dose-response relationship. No plateau was detected. No dose threshold was required for efficacy.
[0210] The specific endpoints chosen for these studies – all direct or indirect indicators of good skin health – are related to the ability of the vesicular concentrate to blend perfectly with the skin, meaning it acts as a barrier – as the concentrate has a biomimetic effect on the skin – reinforcing the skin’s protective capacity and broadening its intrinsic functions, inducing rapid renewal / rejuvenation activity, with noticeable results in terms of improving skin tone and reducing wrinkles.
[0211] Overall, vesicular concentrates are a versatile and flexible tool: adding them to cosmetic formulations can bring about their beneficial effects on the skin barrier - in proportion to any use amount, allowing cosmetic formulators to use them freely in a variety of cosmetic applications. Even with a "light" serum containing vesicular concentrates, the benefits of a rich cream can be obtained.
[0212] Strengthens the skin barrier
[0213] In this second clinical study, a system of vesicle concentrates with different numbers of constituent components was explored to investigate the flexibility of vesicle concentrates, understanding them more as a platform than as complex cosmetic active ingredients made with a specific formulation. Thus, the two endpoints already present in the above study (hydration and wrinkle visibility) were evaluated again, and another specific endpoint was added to evaluate the protection and repair of the skin barrier.
[0214] The formulations tested in this study were identical and differed only in the vesicle concentrate systems contained therein - these systems were formulated differently in terms of the amounts of their constituent ingredients. Thus, four base cream formulations were prepared, three of which contained 10% of each of the different vesicle concentrates:
[0215] - Anti-aging PCS OI8293: Example 2
[0216] - Empty PCS OI8304: Example 1
[0217] -Alternative anti-aging PCS OI8292: Example 2-2
[0218] - The fourth had no vesicle concentrate and served as a placebo.
[0219] The clinical test was conducted on 40 volunteers (aged 40-65 years, female), divided into 4 groups, 10 people in each group; each group was assigned one of the four formulations.
[0220] For the TEWL endpoint, the study was conducted as follows.
[0221] For the hydration and visibility factors, the product was first applied to the face under controlled conditions in a clinical center.
[0222] Subsequently, the volunteers continued to use the product, applying it twice a day (morning and evening) for 2 weeks (14 days) as instructed. They then stopped using the test product and any other cosmetic products on their faces for 7 days.
[0223] Instrumental measurements of hydration and visibility coefficients were performed on the faces of volunteers treated with the specified products (test areas) and on untreated areas of the forearms (control areas) at the following time points: immediately before product application (tb), 2 hours after the first application of the product (t2h), after two weeks (14 days) of daily application of the product (twice a day) (t2w), and after 7 days of suspension of the use of the product and any other cosmetic products (t3w).
[0224] Taking into account the effects of temperature and relative humidity on the skin, volunteers were kept under controlled conditions (range: 22±2°C and 50±5%, respectively) for at least 20 minutes before measurement.
[0225] 5.1.1TEWL (Transepidermal Water Loss)
[0226] 5.1.2 Hydration
[0227] 5.1.3 Wrinkle visibility
[0228] 5.1.1 Effect of enhancing skin barrier
[0229] Protection against environmental stressors - immediate effect measured by TEWL (transepidermal water loss) after peeling.
[0230] TEWL is a measure of the integrity of the skin's "barrier function". By inducing an initial photodamage to the skin under controlled conditions (15 consecutive skin strippings), the increase in TEWL is determined.
[0231] The efficacy of the vesicular concentrate in protecting / repairing the skin barrier thus altered was evaluated by comparing the TEWL recovery rate of damaged skin and damaged and untreated skin treated with the vesicular concentrate over short periods of time (30, 60 and 120 minutes), as well as comparing the behavior of a placebo formulation without the vesicular concentrate.
[0232] result
[0233] The results of this study are summarized in Fig.15 The figure shows the percentage recovery of TEWL values after injury (skin peeling) for different formulations containing vesicle concentrates and placebo, relative to the injured skin not treated with any product.
[0234] All tested formulations restored the skin barrier more rapidly (TEWL reduction) in a significantly higher manner compared to the comparative placebo formulation (without vesicle concentrate).
[0235] 5.1.2 Increased hydration
[0236] Similar to what was described in the first study, in this case the hydration efficacy of the tested formulas was tested by instrumental measurement of skin hydration (keratometer CM825 - Courage + Khazaka) after a single application (2 h), after repeated daily dosing for 14 days and after a further 7 days after cessation of treatment.
[0237] result
[0238] The table below reports the skin hydration data obtained from the experiment (whose effectiveness was statistically evaluated) providing the percentage difference relative to the baseline value at the different measurement times for each test product.
[0239] It can be easily observed that all three cream formulas containing vesicular concentrate are very effective in increasing the hydration value immediately (value at 2 hours), which is maintained throughout the use period of the product. This increase is significantly higher than that achieved by the placebo, which has the same formula but does not contain vesicular concentrate.
[0240] Small differences detected in the untreated area (forearm) were not statistically significant.
[0241] After one week of suspension of application, hydration basically returned to the initial value.
[0242]
[0243] By comparing the hydration increment values achieved at the different measuring time points with formulation OI8304 in this experiment (+30.51% at 2 hours; +28.57 at 14 days) and with the same formulation in the first experiment (vesicle concentrate 10%: +24.59% at 6 hours; +23.91% at 14 days), a good overlap of the results can be observed, considering that these results were obtained on two different groups of volunteers (10 people each) and at different times.
[0244] 5.1.3 Improve facial skin appearance
[0245] Wrinkle visibility factor reduced
[0246] As explained in the first clinical study above, the aim here was to evaluate the efficacy of restoring the normal characteristics of skin micro-lines, reducing the appearance of fine wrinkles, and improving skin smoothness and overall appearance.
[0247] To summarize the above, the method is based on the measurement of wrinkle visibility in facial photographic images obtained by a system that allows the acquisition of standardized photographs of the front and side views under polarized parallel light (+ / -45° - HeadScan Dynamics, OrionTechnoLab, France). Dedicated software ensures acquisition under reproducible lighting and filming conditions.
[0248] From these images, a “wrinkle visibility” index was calculated that correlated well with clinical perception of wrinkles.
[0249] Visibility coefficient = (wrinkle occupancy) * (comparative wrinkles / skin) * 100
[0250] result
[0251] The table below summarizes the results of this part of the study.
[0252]
[0253] In this case, it can also be noted that the tested vesicle concentrates behaved almost identically: all of them allowed to significantly reduce the visibility of wrinkles, while the effect of the placebo was not very effective.
[0254] After suspending the use of the product, the visibility coefficient returned almost to the baseline value, similar to the same parameter observed in the first study.
[0255] Overall, no significant differences emerged between the different vesicle concentrate systems tested for the three endpoints considered in the study, confirming that the composition of vesicle concentrates can be varied to suit different cosmetic applications while maintaining their high efficacy.
[0256] Fig.16 Shows what happens on the skin after applying a cream containing a vesicle concentrate according to the invention. During application, the vesicles are spaced a certain distance apart due to the presence of water in the cream (first scheme on the right). After the water evaporates naturally, the vesicles flatten to form a protective film (second scheme on the right). The two pictures of cryo-TEM and TEM on the left show their effect on the skin.
[0257] Fig.17 A comparison between microvesicles on the left and nanovesicles on the right is shown. The evaporation of water is constant and micron-sized (0.6-1.0 μm) vesicles (such as the vesicles of the present invention) form a more effective barrier than barriers made of nano-sized (diameter <100 nm) vesicles.
[0258] Apparently, the barrier effect of the vesicles is additive to that of the active ingredients that the vesicles can enhance, such as panthenol, oat (avena sativa) kernel proteins, ectoine, 3-o-ethylascorbic acid, and niacinamide, which take longer (2-4 weeks) to exert their effects.
[0259] Example 1 - Formulation of vesicle concentrate
[0260] Mutually Element %weight Phase A glycerin 36 (a) Hydrogenated phosphatidylcholine 10 (a) Lecithin 2 (d) Sodium β-Sitosterol Sulfate 0.20 (c) Phytosteryl Isostearate 0.60 (c) β-Sitosterol 2 (e) Ceramide np 2 (b) Phytosphingosine 2 Squalane 10 Tocopheryl acetate 0.1 Caprylyl Glycol 1.1 Phase b water 30 Panthenol 4 total 100.00
[0261] Example 2 - Formulation of vesicular concentrates with lipophilic and hydrophilic active ingredients
[0262]
[0263]
[0264] Example 2-2 - Formulation of vesicle concentrates with lipophilic and hydrophilic active ingredients
[0265]
[0266]
[0267] Example 3 - Formulation of vesicular concentrates with lipophilic and hydrophilic active ingredients
[0268]
[0269] Example 3-2 - Formulation of vesicle concentrate with lipophilic and hydrophilic active ingredients and added fatty acids
[0270]
[0271]
[0272] Example 3-3 - Formulation of Vesicle Concentrate with High Phospholipid Content
[0273] Mutually Element %weight Phase A glycerin 20 Hydrogenated phosphatidylcholine 16 Lecithin 12 Sodium β-Sitosterol Sulfate 0.20 Phytosteryl Isostearate 0.60 β-Sitosterol 2 Ceramide np 2 Phytosphingosine 2 Squalane 10 Tocopheryl acetate 0.1 Caprylyl Glycol 1.1 Phase B water 30 Panthenol 4 total 100.00
[0274] As described in claim 1, the content range of components (a) to (e) in different embodiments 1-3 ter is always 15-40%.
[0275] Example 4 - Cream formulation with 10% vesicle concentrate
[0276] Element %weight water 62.85 Cellulose 15.00 Xylitol 2.20 Betaine 0.60 Sodium Hyaluronate 0.05 Carbomer 0.70 Pentylene glycol 2.20 Sorbitan octanoate 0.25 Caprylic / capric triglyceride 2.00 Squalane 1.50 Behenyl alcohol 2.00 Arginine 0.65 Vesicle concentrate according to Examples 1, 2, and 3 10.00 total 100.00
[0277] Example 5 - Facial serum formula with 5% vesicle concentrate
[0278] Element %weight water 91.00 Erythritol 3.00 Tamarindus indicus seed gum 0.60 Hydroxyacetophenone 0.15 Phenoxyethanol 0.25 Vesicle concentrate according to Examples 1, 2, and 3 5.00 total 100.00
[0279] Example 6 - Facial serum formula with 20% vesicle concentrate
[0280]
[0281] Example 7 - Body Cream Formulation with 24% Vesicle Concentrate
[0282]
[0283] Example 8 - Formulation of powder product
[0284]
[0285] Example 8 provides mixing phase A with phase B by means of a powder mixer and drying the treated powder in a ventilated oven at 50° C. until completely dry, then sieving through a screen 120 and compacting in a godet roll.
Claims
1. A cosmetic composition comprising a vesicle concentrate consisting of an aqueous solution of lipid vesicles, characterized in that The lipid vesicles are multilamellar vesicles with a size range of 0.6-1.0 microns, whose walls are formed by: (a) Phospholipids (b) Phytosphingosine (c) Phytosterols (d) β-phytosterol sulfate and optionally, other derivatives of phytosterol (e) Ceramide and / or ceramide-like The weight content of components (a) to (e) ranges from 15-40% of the vesicle concentrate composition.
2. The cosmetic composition according to claim 1, wherein All of the ingredients described are either plant ingredients or of plant origin. 3 . The cosmetic composition according to claim 1 , further comprising lysophospholipid as ingredient (f).
4. The cosmetic composition according to any preceding claim, further comprising as ingredient (g) an ester of phytosterols.
5. The cosmetic composition according to any preceding claim, further comprising as ingredient (h) a fatty acid, in particular one or a mixture of oleic acid, palmitic acid, coconut fatty acids.
6. The cosmetic composition according to any preceding claim, further comprising a humectant, in particular one or a mixture of glycerol, xylitol, sorbitol, isosorbide, butylene glycol, as ingredient (i).
7. The cosmetic composition according to any of the preceding claims, further comprising an emollient, in particular one or a mixture of phytosqualane, phytosqualene, hemisqualane, caprylic / capric triglyceride, cetyl palmitate, cetearyl ethylhexanoate, octyldodecanol, dimethicone, as ingredient (1).
8. The cosmetic composition according to any preceding claim, further comprising a preservative, in particular one or a mixture of sorbitan octanoate, 1,2-hexanediol, hydroxyacetophenone, as ingredient (m).
9. The cosmetic composition according to any preceding claim, further comprising a lipophilic active molecule, in particular one or a mixture of tocopherol acetate, tocopherol nicotinate, retinol, tocopherol, ethyl ferulate, ethyl linoleate, as ingredient (n).
10. The cosmetic composition according to any preceding claim, further comprising a hydrophilic active molecule, in particular one or a mixture of ectoine, d-panthenol, nmf factor, ascorbyl glucose ester, sodium ascorbyl phosphate, myo-inositol, acetyl glucosamine, alanyl glutamine, acetylcysteine, as ingredient (o).
11. The cosmetic composition according to any preceding claim, further comprising a thickener, in particular one or a mixture of xanthan gum, cellulose gum, hyaluronic acid, dextran, sodium acrylate network polymer, polyquaternium-37, carrageenan, alginate derivatives, guar gum derivatives, as ingredient (p).
12. The cosmetic composition according to any of the preceding claims, further comprising, as ingredient (q), a film-forming molecule, in particular one or a mixture of zein, oat protein, rice protein, hydrolyzed rice protein.
13. A cosmetic product comprising the cosmetic composition according to any one of claims 1 to 12 and any other cosmetically acceptable ingredients.
14. The cosmetic product according to claim 13, comprising 0.1% to 60% by weight of the cosmetic composition.
15. A method for obtaining a cosmetic product according to claim 13 or 14, comprising: Preparation of plant or plant-derived biomimetic vesicles in the size range of 0.6-1.0 μm, the wall of which comprises a lipid phase having a component according to any one of claims 1-12, comprising the following sub-steps: o preparing a composition comprising a vesicle concentrate by melting the walls of the vesicles to a liquid crystal melt state to obtain a homogeneous single-phase system; o introducing an aqueous phase into the vesicle concentrate composition at a temperature above the solidification temperature of the lipid phase of the vesicles; o cooling the vesicle concentrate composition to a temperature below the solidification temperature of the lipid phase of the vesicles until a material having a pasty texture with the rheological properties of a pseudoplastic fluid or a viscoelastic solid is obtained, wherein the size distribution of the vesicles is between 0.6 and 1.0 microns; The obtained vesicle concentrate composition having a pasty texture is mixed with water and other cosmetic ingredients until a finished cosmetic product containing the desired weight percentage of the vesicle concentrate is obtained.
16. The method for preparing a cosmetic product according to claim 15, wherein the vesicle concentrate is obtained by the following steps: The ingredients of the vesicle wall (phase A) are inserted one at a time into a jacketed mixer equipped with a turbine (rotor-stator), mechanical stirring and wipers; The mixture is mechanically stirred at room temperature until a uniform and homogeneous dispersion of the components is obtained; Phase A was gradually heated in 10°C increments over a period of 1 hour until the temperature reached 80-100°C to allow the solid ingredients to melt, obtaining a translucent dispersion with a pasty texture and a slightly yellowish color; Heat phase A at 60°C and continue mechanical stirring; Gradually add the components to be added to the vesicle (phase B) into the mixer, keeping the temperature constant; Once the addition of phase B is complete, stir the composition for 30 minutes; The mixture was stirred turbulently, the turbine was started and the temperature was gradually lowered to room temperature to obtain a concentrate having the appearance of a white / light yellow paste.
17. The method according to claim 15, wherein: The other cosmetic ingredients consist of cosmetic powders, and a final drying step is provided for removing water and obtaining a powder cosmetic product comprising the vesicle concentrate composition and cosmetic powders.
Citation Information
Cited By
Bionic sebum film lipid nanoparticle with repairing function, preparation method, application and product
CN120131489A
Bionic sebum membrane lipid nanoparticles with repairing function, preparation method, application and product
CN120131489B
Preparation method of vesicle salicylic acid
CN121818407A
